Stocks Health care HRGN
OTC · Health careHarvard Apparatus Regenerative Technology, Inc. (HRGN)
Harvard Apparatus Regenerative Technology, Inc. brought in $982K of revenue over the twelve months to June 30, 2026, up 44.6% from a year earlier. It posted a net loss of $6.7M. At June 30, 2026 it held $351K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Watch HRGN in 60 secondsWhat Harvard Apparatus Regenerative Technology, Inc. does
Harvard Apparatus Regenerative Technology, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on OTC under the ticker HRGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $704K | -$6.9M | -$0.42 | n/a |
| 2024 | $430K | -$7.7M | -$0.52 | -$4.9M |
| 2023 | $103K | -$8.9M | -$0.67 | -$7M |
| 2022 | n/a | -$6.1M | -$0.55 | -$5.1M |
| 2021 | $0 | -$8M | -$0.79 | -$2.6M |
| 2020 | $0 | -$4.9M | -$0.55 | -$4M |
Full financial statements: income, balance sheet and cash flow
Where HRGN ranks in Health care
Latest SEC filings
What Harvard Apparatus Regenerative Technology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 31% to $414K versus the same quarter last year; diluted EPS -$0.10 versus -$0.11.
- August 3, 2026
- August 3, 2026Material agreement 8-K/A
- June 24, 2026
- May 13, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 402% to $226K versus the same quarter last year; diluted EPS -$0.09 versus -$0.10.
- April 28, 2026
- April 23, 2026Proxy statement DEF 14A
- April 15, 2026
- March 19, 2026Annual report 10-K · period to December 31, 2025Revenue rose 64% to $704K versus the prior year; diluted EPS -$0.42 versus -$0.52.
Insider trades
What the people running Harvard Apparatus Regenerative Technology, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $394.5K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 15, 2026 | He JunliCEO, Director | Bought | 6,725 | $14.5K |
| September 11, 2026 | He JunliCEO, Director | Exercised options | 683,725 | $717.9K |
| September 11, 2026 | He JunliCEO, Director | Bought | 361,905 | $380K |
| November 25, 2025 | He JunliCEO, Director | Bought | 3,000 | $5.1K |
| September 30, 2025 | He JunliCEO, Director | Bought | 300 | $594 |
Who owns HRGN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
1 insiders reported holding 1,332,930 shares in total, about $2.9M at the last price.
| Holder | Shares |
|---|---|
| He JunliCEO, Director | 1,332,930 |
Questions about HRGN
What does Harvard Apparatus Regenerative Technology, Inc. do?
Harvard Apparatus Regenerative Technology, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on OTC under the ticker HRGN.
Is Harvard Apparatus Regenerative Technology, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $6.7M on revenue of $982K.
How much revenue does Harvard Apparatus Regenerative Technology, Inc. make?
Over the twelve months to June 30, 2026 Harvard Apparatus Regenerative Technology, Inc. reported revenue of $982K. That is 44.6% more than a year earlier.
When did Harvard Apparatus Regenerative Technology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 25, 2026.
Similar companies
Compare HRGN with
Follow HRGN
Get an email when Harvard Apparatus Regenerative Technology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow HRGN: get an email when it filesWhere the numbers come from
Financial figures are the values Harvard Apparatus Regenerative Technology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.